ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results

Rhea-AI Summary

ImmunoGen Inc. (Nasdaq: IMGN) announced a conference call scheduled for 8:00 a.m. ET on July 30, 2021, to discuss its second-quarter operating results. The call will also include a brief update on the company's business. Investors can access the call by dialing (877) 621-5803 with conference ID 1789134 or through the company's website. A replay will be available post-call. ImmunoGen focuses on developing advanced antibody-drug conjugates (ADCs) to improve cancer treatment outcomes.

Positive

• Scheduled conference call to discuss second-quarter operating results, indicating transparency and communication with stakeholders.

Negative

• None.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 30, 2021 to discuss its second quarter operating results. Management will also provide a brief update on the business.

Conference Call Information

To access the live call by phone, dial (877) 621-5803; the conference ID is 1789134. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005001/en/

FAQ

What is the purpose of ImmunoGen's conference call on July 30, 2021?

The conference call aims to discuss ImmunoGen's second-quarter operating results and provide a business update.

How can I access the ImmunoGen conference call?

You can access the call by dialing (877) 621-5803 with conference ID 1789134, or through the Investors and Media section of ImmunoGen's website.

What is ImmunoGen's focus in the biopharmaceutical industry?

ImmunoGen is focused on developing next-generation antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

What time is ImmunoGen's conference call scheduled for?

The conference call is scheduled for 8:00 a.m. ET on July 30, 2021.